+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Minimal Residual Disease Testing Market - Global Forecast 2026-2032- Product Image
Minimal Residual Disease Testing Market - Global Forecast 2026-2032- Product Image
New

Minimal Residual Disease Testing Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 185 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5847005
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Minimal residual disease (MRD) testing is transforming how healthcare systems detect, monitor, and manage residual disease, intersecting technology innovation, clinical integration, and operational effectiveness, and prompting new decision points for senior leaders.

Market Snapshot

The Minimal Residual Disease Testing Market grew from USD 2.08 billion in 2025 to USD 2.31 billion in 2026. It is expected to continue expanding at a CAGR of 11.55%, reaching USD 4.47 billion by 2032. This growth is driven by advancements in testing accuracy, adoption in clinical routines, and expanding applications across oncology indications.

Scope & Segmentation

  • Assay Modalities: Flow cytometry, next-generation sequencing (NGS), polymerase chain reaction (PCR), and cytogenetic methods are critical to detection. Each technology offers distinct benefits, from high sensitivity to rapid turnaround and cost efficiency.
  • Clinical Applications: MRD testing supports monitoring and management in leukemia, lymphoma, multiple myeloma, and select solid tumors. Different oncology subtypes require tailored markers, assay protocols, and interpretation criteria.
  • End-User Priorities: Academic institutes focus on innovative protocol development; biopharmaceutical companies emphasize standardized, validated assays; diagnostic laboratories require scalable, efficient workflows; hospitals prioritize clinical integration and actionable results.
  • Regional Coverage: Americas feature diverse lab networks and strong clinical research; EMEA shows varied regulatory systems and infrastructure; Asia-Pacific emphasizes automation, growing molecular diagnostics investment, and scalable solutions.

Key Takeaways

  • MRD testing is a convergence of technical innovation and evolving clinical evidence, providing a key biomarker for risk profiling and treatment guidance.
  • Operational success depends on cross-functional collaboration—assay selection, workflow integration, specimen logistics, data interpretation, and multi-disciplinary communication all drive effective adoption.
  • Standardized, clinician-focused reporting frameworks facilitate integration with care pathways and support consistent application in therapy decisions.
  • Shifting payer policies, regulatory expectations, and reimbursement models are reshaping test adoption criteria and accelerating the demand for robust evidence of clinical utility.
  • Strategic partnerships among diagnostics vendors, instrument manufacturers, and biopharma sponsors promote coordinated product development and streamlined deployment of MRD solutions.
  • Developing supply chain resilience, evidence-driven reimbursement strategies, and responsive governance models are now essential for program scalability.

Tariff Impact on the MRD Testing Market

Recent tariff measures affect procurement and capital planning for laboratories and clinical trial sponsors. Increased costs of key reagents and instrumentation due to cross-border supply chain dependencies prompt organizations to renegotiate supplier terms, consolidate sourcing, or accelerate local procurement initiatives. In response, labs are prioritizing supplier diversification and long-term agreements, while sponsors centralize certain trial activities to regions with stable trade conditions. Supply chain resilience is now a core consideration in safeguarding operational continuity.

Methodology & Data Sources

This report integrates primary interviews with laboratory directors, clinical investigators, and procurement specialists alongside workflow observations. Secondary research includes deep reviews of peer-reviewed literature, clinical guidelines, public company reports, and regulatory notices. Findings are validated through qualitative coding and process mapping, prioritizing transparency, reproducibility, and clear alignment with real-world priorities.

Why This Report Matters

  • Enables leadership to calibrate MRD testing investments to evolving clinical, operational, and regulatory landscapes.
  • Provides actionable strategies to align laboratory capabilities, clinical pathways, and commercial targets with supply and reimbursement dynamics.
  • Equips stakeholders to anticipate future shifts in policy and technology, improving decision confidence across procurement and deployment.

Conclusion

MRD testing is pivotal for precision oncology and value-based care. Success depends on aligning technology, operations, and clinical requirements while navigating a complex policy and reimbursement landscape. Organizations that prioritize evidence generation and process standardization will secure greater clinical and commercial value within this evolving market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Minimal Residual Disease Testing Market, by Test Type
8.1. Cytogenetics
8.1.1. Chromosomal microarray
8.1.2. Fluorescence in situ hybridization (FISH)
8.2. Flow Cytometry
8.2.1. Multi-parameter flow cytometry
8.2.2. Single-parameter flow cytometry
8.3. Next-Generation Sequencing (NGS)
8.3.1. Targeted sequencing
8.3.2. Whole genome sequencing
8.4. Polymerase Chain Reaction (PCR)
8.4.1. Digital PCR
8.4.2. Quantitative PCR
9. Minimal Residual Disease Testing Market, by Sample Type
9.1. Blood
9.1.1. Plasma
9.1.2. Serum
9.2. Bone Marrow
9.3. Cerebrospinal Fluid (CSF)
9.4. Tissue Biopsy
9.5. Urine
10. Minimal Residual Disease Testing Market, by Application Areas
10.1. Leukemia
10.1.1. Acute Lymphoblastic Leukemia (ALL)
10.1.2. Acute Myeloid Leukemia (AML)
10.1.3. Chronic Lymphocytic Leukemia (CLL)
10.2. Lymphoma
10.2.1. Hodgkin’s lymphoma
10.2.2. Non-Hodgkin’s lymphoma
10.3. Multiple Myeloma
10.4. Solid Tumors
10.4.1. Breast cancer
10.4.2. Colorectal cancer
11. Minimal Residual Disease Testing Market, by End-User Vertical
11.1. Academic & Research Institutes
11.2. Biopharmaceutical Companies
11.3. Diagnostic Laboratories
11.4. Hospitals
12. Minimal Residual Disease Testing Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Minimal Residual Disease Testing Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Minimal Residual Disease Testing Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. United States Minimal Residual Disease Testing Market
16. China Minimal Residual Disease Testing Market
17. Competitive Landscape
17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. Adaptive Biotechnologies Corporation
17.6. Agilus Diagnostics Ltd.
17.7. Amgen Inc.
17.8. ARUP Laboratories
17.9. AstraZeneca PLC
17.10. Asuragen Inc. by Bio-Techne Corporation
17.11. Bio-Rad Laboratories, Inc.
17.12. Bristol-Myers Squibb Company
17.13. C2I Genomics Inc.
17.14. Cergentis B.V.
17.15. Exact Sciences Corporation
17.16. F. Hoffmann-La Roche Ltd.
17.17. Genetron Holdings Limited
17.18. GRAIL, LLC by Illumina, Inc.
17.19. Guardant Health, Inc.
17.20. Integrated DNA Technologies, Inc.
17.21. Invivoscribe, Inc.
17.22. Kite Pharma, Inc. by Gilead Sciences, Inc.
17.23. Laboratory Corporation of America Holdings
17.24. Mdxhealth BV
17.25. MedGenome Inc
17.26. Mission Bio, Inc.
17.27. Myriad Genetics, Inc.
17.28. Natera Inc.
17.29. NeoGenomics Laboratories, Inc.
17.30. OPKO Health, Inc.
17.31. Quest Diagnostics incorporated
17.32. Sysmex Corporation
17.33. Veracyte, Inc.
List of Figures
FIGURE 1. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CHROMOSOMAL MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CHROMOSOMAL MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CHROMOSOMAL MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTI-PARAMETER FLOW CYTOMETRY, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTI-PARAMETER FLOW CYTOMETRY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTI-PARAMETER FLOW CYTOMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SINGLE-PARAMETER FLOW CYTOMETRY, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SINGLE-PARAMETER FLOW CYTOMETRY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SINGLE-PARAMETER FLOW CYTOMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
TABLE 27. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
TABLE 37. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY QUANTITATIVE PCR, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY QUANTITATIVE PCR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY QUANTITATIVE PCR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BONE MARROW, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BONE MARROW, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BONE MARROW, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CEREBROSPINAL FLUID (CSF), BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CEREBROSPINAL FLUID (CSF), BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CEREBROSPINAL FLUID (CSF), BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TISSUE BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TISSUE BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACUTE MYELOID LEUKEMIA (AML), BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACUTE MYELOID LEUKEMIA (AML), BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACUTE MYELOID LEUKEMIA (AML), BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HODGKIN’S LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HODGKIN’S LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HODGKIN’S LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NON-HODGKIN’S LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NON-HODGKIN’S LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NON-HODGKIN’S LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 117. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 118. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 119. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
TABLE 120. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 121. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
TABLE 122. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
TABLE 123. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 124. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
TABLE 125. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
TABLE 126. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 127. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
TABLE 128. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 129. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
TABLE 130. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 131. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 132. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
TABLE 133. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 134. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
TABLE 135. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
TABLE 136. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 137. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
TABLE 138. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
TABLE 139. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 140. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
TABLE 141. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 142. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
TABLE 143. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 144. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 145. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
TABLE 146. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 147. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
TABLE 148. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
TABLE 149. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 150. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
TABLE 151. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
TABLE 152. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 153. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
TABLE 154. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 155. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
TABLE 169. EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 170. EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 171. EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
TABLE 172. EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 173. EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
TABLE 174. EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
TABLE 175. EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 176. EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
TABLE 177. EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
TABLE 178. EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 179. EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
TABLE 180. EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 181. EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
TABLE 182. MIDDLE EAST MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 183. MIDDLE EAST MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 184. MIDDLE EAST MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
TABLE 185. MIDDLE EAST MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 186. MIDDLE EAST MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
TABLE 187. MIDDLE EAST MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
TABLE 188. MIDDLE EAST MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 189. MIDDLE EAST MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
TABLE 190. MIDDLE EAST MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
TABLE 191. MIDDLE EAST MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 192. MIDDLE EAST MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
TABLE 193. MIDDLE EAST MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 194. MIDDLE EAST MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
TABLE 195. AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 196. AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 197. AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
TABLE 198. AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 199. AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
TABLE 200. AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
TABLE 201. AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 202. AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
TABLE 203. AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
TABLE 204. AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 205. AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
TABLE 206. AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 207. AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
TABLE 208. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 209. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 210. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
TABLE 211. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 212. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
TABLE 213. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
TABLE 214. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 215. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
TABLE 216. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
TABLE 217. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 218. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
TABLE 219. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 220. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
TABLE 221. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 222. ASEAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 223. ASEAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 224. ASEAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
TABLE 225. ASEAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 226. ASEAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
TABLE 227. ASEAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
TABLE 228. ASEAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 229. ASEAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
TABLE 230. ASEAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
TABLE 231. ASEAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 232. ASEAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
TABLE 233. ASEAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 234. ASEAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
TABLE 235. GCC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 236. GCC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 237. GCC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
TABLE 238. GCC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 239. GCC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
TABLE 240. GCC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
TABLE 241. GCC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 242. GCC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
TABLE 243. GCC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
TABLE 244. GCC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 245. GCC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
TABLE 246. GCC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 247. GCC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
TABLE 248. EUROPEAN UNION MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 249. EUROPEAN UNION MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 250. EUROPEAN UNION MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
TABLE 251. EUROPEAN UNION MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 252. EUROPEAN UNION MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
TABLE 253. EUROPEAN UNION MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
TABLE 254. EUROPEAN UNION MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 255. EUROPEAN UNION MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
TABLE 256. EUROPEAN UNION MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
TABLE 257. EUROPEAN UNION MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 258. EUROPEAN UNION MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
TABLE 259. EUROPEAN UNION MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 260. EUROPEAN UNION MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
TABLE 261. BRICS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 262. BRICS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 263. BRICS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
TABLE 264. BRICS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 265. BRICS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
TABLE 266. BRICS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
TABLE 267. BRICS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 268. BRICS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
TABLE 269. BRICS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
TABLE 270. BRICS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 271. BRICS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
TABLE 272. BRICS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 273. BRICS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
TABLE 274. G7 MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 275. G7 MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 276. G7 MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
TABLE 277. G7 MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
TABLE 278. G7 MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
TABLE 279. G7 MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
TABLE 280. G7 MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 281. G7 MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
TABLE 282. G7 MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
TABLE 283. G7 MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
TABLE 284. G7 MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
TABLE 285. G7 MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 286. G7 MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
TABLE 287.

Companies Mentioned

The key companies profiled in this Minimal Residual Disease Testing market report include:
  • Adaptive Biotechnologies Corporation
  • Agilus Diagnostics Ltd.
  • Amgen Inc.
  • ARUP Laboratories
  • AstraZeneca PLC
  • Asuragen Inc. by Bio-Techne Corporation
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Company
  • C2I Genomics Inc.
  • Cergentis B.V.
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Genetron Holdings Limited
  • GRAIL, LLC by Illumina, Inc.
  • Guardant Health, Inc.
  • Integrated DNA Technologies, Inc.
  • Invivoscribe, Inc.
  • Kite Pharma, Inc. by Gilead Sciences, Inc.
  • Laboratory Corporation of America Holdings
  • Mdxhealth BV
  • MedGenome Inc
  • Mission Bio, Inc.
  • Myriad Genetics, Inc.
  • Natera Inc.
  • NeoGenomics Laboratories, Inc.
  • OPKO Health, Inc.
  • Quest Diagnostics incorporated
  • Sysmex Corporation
  • Veracyte, Inc.

Table Information

Report AttributeDetails
No. of Pages185
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 2.31 Billion
Forecasted Market Value ( USD ) by 2032 $ 4.47 Billion
Compound Annual Growth Rate11.5%
Regions CoveredGlobal
No. of Companies Mentioned30

Related Topics

Related Reports

Minimal Residual Disease Testing - Market Insights, Competitive Landscape, and Market Forecast - 2032 - Product Image

Minimal Residual Disease Testing - Market Insights, Competitive Landscape, and Market Forecast - 2032

  • Report
  • 150 Pages
  • Global
From
Minimal Residual Disease Testing Market Report: Size, Share, Growth Drivers, Trends, Opportunities & Forecast 2025-2030 - Product Image

Minimal Residual Disease Testing Market Report: Size, Share, Growth Drivers, Trends, Opportunities & Forecast 2025-2030

  • Report
  • 90 Pages
  • Global
From
Minimal Residual Disease Testing - Global Strategic Business Report - Product Image

Minimal Residual Disease Testing - Global Strategic Business Report

  • Report
  • 383 Pages
  • Global
From
Minimal Residual Disease Testing Market 2025-2033 - Product Image

Minimal Residual Disease Testing Market 2025-2033

  • Report
  • 138 Pages
  • Global
From
Minimal Residual Disease Testing Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Minimal Residual Disease Testing Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 85 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.